A Study to Evaluate the Effect of KarXT on Urological Safety
NCT07221877
This study is recruiting at 12 US sites in 8 states, according to its ClinicalTrials.gov record last updated .
Summary
The purpose of this study is to characterize the effect of KarXT on voiding dynamics and urological safety in participants with DSM-5 schizophrenia.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Schizophrenia
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 4
- Ages
- 18 to 65 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Bristol-Myers Squibb
- Last updated on ClinicalTrials.gov
- June 3, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Arkansas · 1
- Pillar Clinical Research- Little Rock · Little Rock, AR
California · 3
- Clinical Innovations, Inc. dba CITrials · Bellflower, CA
- CenExel CNS - Garden Grove · Garden Grove, CA
- ATP Clinical Research · Orange, CA
Florida · 2
- Innovative Clinical Research · Lauderhill, FL
- Health Synergy Clinical Research · West Palm Beach, FL
Illinois · 2
- Pillar Clinical Research -Chicago · Chicago, IL
- Uptown Research Institute · Chicago, IL
Nevada · 1
- IMA Clinical Research Las Vegas · Las Vegas, NV
New Jersey · 1
- Hassman Research Institute Marlton Site · Marlton, NJ
Pennsylvania · 1
- Adams Clinical Philadelphia · Philadelphia, PA
Texas · 1
- InSite Clinical Research · DeSoto, TX
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.